Shares are trading at $2.86 which is just a bit higher than $2.60, the 50 day moving average and which is quite a bit above the 200 day moving average of $2.50. The 50 day moving average went up by +9.86% and the 200 day average went up $0.36 or +14.42%. (NASDAQ:CPRX) shares saw heavy trading volume with 1,728K shares changing hands in the last trading session. Overall, volume was up 195.52% over the stocks normal daily volume.
Investors are a little more bullish on Catalyst Pharmaceuticals, Inc. recently if you consider the motion in short interest. The firm saw a fall in short interest between September 29, 2017 and October 13, 2017 of -4.41%. Short interest fell 137,440 over that period. Days to cover decreased -2.0 to 7.0 and the percentage of shorted shares was 0.04% on October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (CPRX). As of the end of the quarter Boothbay Fund Management, LLC had bought 29,275 shares growing its stake by 73.7%. The value of the investment in CPRX went from $97,000 to $190,000 a change of 95.9% quarter to quarter. Candriam Luxembourg S.c.a. downsized its ownership by shedding 40,000 shares a decrease of 6.7%. Candriam Luxembourg S.c.a. controls 560,000 shares with a value of $1,546,000. The value of the position overall is up by 32.1%.
Berson & Corrado Investment Advisors, LLC reduced its position by selling 41,450 shares a decrease of 30.4% from 06/30/2017 to 09/30/2017. Berson & Corrado Investment Advisors, LLC currently owns 95,100 shares worth $240,000. The total value of its holdings decreased 36.3%. As of quarter end Simplex Trading, LLC had disposed of a total of 915 shares trimming its holdings by 26.8%. The value of the total investment in Catalyst Pharmaceuticals, Inc. decreased from $9,000 to $6,000 a change of $3,000 since the last quarter.
As of the last earnings report the EPS was $-0.20 and is expected to be $-0.23 for the current year with 84,554,000 shares now outstanding. Analysts expect next quarter’s EPS to be $-0.06 and the next full year EPS is anticipated to be $-0.25.
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., launched on July 21, 2006, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115..